This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
The beta sheet (β-sheet, also β-pleated sheet) is a common motif of the regular protein secondary structure. Beta sheets consist of beta strands (β-strands) connected laterally by at least two or three backbone hydrogen bonds, forming a generally twisted, pleated sheet. A β-strand is a stretch of polypeptide chain typically 3 to 10 amino acids long with backbone in an extended conformation. The supramolecular association of β-sheets has been implicated in the formation of the fibrils and protein aggregates observed in amyloidosis, Alzheimer's disease and other proteinopathies.
The Crown issued a decree, Código Negro Español (Spanish Black Code), that specified food and clothing provisions, put limits on the number of work hours, limited punishments, required religious instruction, and protected marriages, forbidding the sale of young children away from their mothers. The British made other changes to the institution of slavery in Cuba. However, planters often flouted the laws and protested against them, considering them a threat to their authority and an intrusion into their personal lives.
==== Animal models ==== The safety of adjuvants are often tested using animal models. Model animals are given a dose of the adjuvant (sometimes comparable to real human/animal vaccines, sometimes higher) by injection, at a site that may or may not be analogous to real-life use. For example, aluminium adjuvants can kill motor neurons when subcutaneously injected at the scruff of a mouse's neck; oil–water suspensions such as pristane produces a precursor to lupus when given to mice by intraperitoneal injection; and arthritis-prone rat strains develop rheumatoid arthritis when injected with 0.2–0.3 mL squalene at the tail. All three examples above concern the classical "grandfathered" adjuvants: if a new adjuvant candidate shows these ill effects in animal testing, it would likely not be further developed, let alone becoming widely used. But more importantly, no effect similar to the above has been found in humans during the decades of their use (including among people genetically predisposed to autoimmunity), showing that animal models are not perfect models – nothing can be a perfect model of another thing, after all.
=== CO2 capture by ribulose 1,5-bisphosphate carboxylase === Perhaps the most prevalent carbamate is the one involved in the capture of CO2 by plants. This process is necessary for their growth. The enzyme ribulose 1,5-bisphosphate carboxylase/oxygenase (RuBisCO) fixes a molecule of carbon dioxide as phosphoglycerate in the Calvin cycle. At the active site of the enzyme, a Mg2+ ion is bound to glutamate and aspartate residues as well as a lysine carbamate. The carbamate is formed when an uncharged lysine side chain near the ion reacts with a carbon dioxide molecule from the air (not the substrate carbon dioxide molecule), which then renders it charged, and, therefore, able to bind the Mg2+ ion.
Sources: en.wikipedia.org
This was his best result in Miami since reaching the final in 2018. Zverev began his 2024 clay season seeded fifth at the Monte-Carlo Masters, receiving a bye into the second round and defeating Sebastian Ofner before losing to eventual champion Stefanos Tsitsipas in the third round. As the top seed at the BMW Open, Zverev received a bye into the second round and beat Jurij Rodionov before being upset by world No. 106 Cristian Garín in the quarterfinals. Seeded fourth in Madrid, Zverev reached the fourth round, beating Borna Ćorić and Denis Shapovalov before being upset by 21st seed Francisco Cerúndolo. Seeded third in Rome, Zverev won his sixth Masters title, defeating Aleksandar Vukic, Nuno Borges, Taylor Fritz, Alejandro Tabilo, and Nicolás Jarry in the final. This was his best result in Rome since winning his first Masters 1000 title at the 2017 Italian Open, and his first Masters title since 2021. At the French Open, Zverev contested Rafael Nadal's final match at the French Open, defeating the 14-time champion in straight sets to record Nadal's fourth ever defeat at the event. He went on to reach the semifinals, winning over David Goffin, Tallon Griekspoor, Holger Rune, and Alex de Minaur. He then defeated two-time finalist Casper Ruud to reach his first Major final since the 2020 US Open and his first on clay. In the deciding set of the final match, Alcaraz hit a second serve which was called out by the line judges. However, the chair umpire overruled the call, declaring the ball in.
In 1905, the Cossack hosts experienced deep mobilization of their menfolk amid the fighting of the Russo-Japanese War in Manchuria and the outbreak of revolution within the Russian Empire. Like other peoples of the empire, some Cossack stanitsas voiced grievances against the regime by defying mobilization orders, or by making relatively liberal political demands. But these infractions were eclipsed by the prominent role of Cossack detachments in stampeding demonstrators and restoring order in the countryside. Subsequently, the wider population viewed the Cossacks as instruments of reaction. Tsar Nicholas II reinforced this concept by issuing new charters, medals, and bonuses to Cossack units in recognition for their performance during the Revolution of 1905. In September 1906, reflecting the success of the Cossacks in putting down the Revolution of 1905, Polkovnik (Colonel) Vladimir Liakhov was sent to Iran to command the train and lead the Persian Cossack Brigade. Liakhov had led a Cossack squad in putting down the revolution in the Caucasus, and following the outbreak of the Constitutional Revolution in Iran he was sent to Tehran to recognize the Cossack Brigade as a force for power to the shah. The Persian Cossack Brigade had not been paid for months and proved to be dubious loyalty to the House of Qajar during the Constructional revolution while its Russian officers were uncertain what to do with Russia itself in revolution.
=== Peroxide stress response === In response to an increased flux of hydrogen peroxide and other organic peroxides such as tert-butyl hydroperoxide and cumene hydroperoxide, peroxide stimulon gets activated. Studies of E. coli response to H2O2 have shown that exposure to H2O2 elevated mRNA levels of 140 genes, of which 30 genes are members of the OxyR regulon. The genes include many genes coding for metabolic enzymes and antioxidant enzymes demonstrating the role of these enzymes in reorganization of metabolism under stress conditions.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.